MFN2 and Alzheimer disease: Pharmacological anti‐dementia agent rivastigmine that modulates MAMs by perturbing the MAM‐anchoring MFN2 and MAM‐resident sterol O‐acyltransferase 1 (SOAT1),49 lowered Aβ generation from a 3D ReN‐GA neuronal model of AD (Figure 1).